Tributyrin enhances the cytotoxic activity of interleukin-2/interleukin-12 stimulated human natural killer cells against LS 174T colon cancer cells in vitro

Cancer Immunology, Immunotherapy

Volumn 50, Issue 2, 2001, Pages 69-76

  Schroder C P ^a   Maurer, H R ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

IL 12; IL 2; LS 174T colon cancer cells; NK cell cytotoxicity; Tributyrin

Indexed keywords

FAS ANTIGEN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA1; TRIBUTYRIN;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; COLON CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNOCYTOTOXICITY; NATURAL KILLER CELL; PRIORITY JOURNAL;

COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, NATURAL; TRANSFORMING GROWTH FACTOR BETA; TRIALKYLTIN COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0035020905     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620100170     Document Type: Article

References (32)

1. Fas-mediated cytotoxicity by freshly isolated natural killer cells
2. Antitumor activity of IL-12 in preclinical models
3. Tributyrin: A prodrug of butyric acid for potential clinical application in differentiation therapy
4. Phase I study of the oral administered butyrate prodrug, tributyrin, in patients with solid tumors
5. Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-FU resistance
6. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts
7. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats
8. Evaluation of the MTT and SRB assays for testing LAK cell-mediated growth inhibition of various adherent and non-adherent tumor target cells
9. Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of short-chain fatty acid butyrate, is associated with mitochondrial activity
10. Induction of antigen presentation by macrophages after phagocytosis of tumor apoptotic cells
11. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes
12. Augmented human tumor cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma
13. CD95's deadly mission in the immune system
14. Differentiation therapy
15. Clinical effects and toxicity of interleukin-2 in patients with cancer
16. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines
17. Komplementäre Onkologie: Kann man sie heute wissenschaftlich begründen?
18. Taxotere inhibits the proliferation and induces differentiation of HL-60 and K562 human myeloid leukemia cells in vitro
19. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity
20. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
21. Butyrate as a differentiating agent: Pharmacokinetics, analogues and current status
22. An interleukin-2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis
23. Differential effects of IL-12 and IL-2 on expression and function of cellular adhesion molecules on purified human natural killer cells
24. Immunological effects of interleukin-12 administered by bolus intravenous injection to patients with cancer
25. Effects of transforming growth factor-β on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness
26. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
27. Tributyrin induces growth inhibitory and differentiating effects on HT29 colon cancer cells in vitro
28. Target structures involved in natural killing: Characteristics, distribution, and candidate molecules
29. Chemotherapy, radiotherapy, and immunotherapy of colorectal neoplasia
30. Human colonic adenocarcinoma cells. Establishment and description of a new line
31. 1 in patients with colorectal cancer: Association with disease progression
32. The role of Fas/FasL in immunosuppression induced by human tumors